Приказ основних података о документу
-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis
dc.creator | Jančić, Ivan | |
dc.creator | Arsenović-Ranin, Nevena | |
dc.creator | Sefik-Bukilica, Mirjana | |
dc.creator | Živojinović, Slađana | |
dc.creator | Damjanov, Nemanja | |
dc.creator | Spasovski, Vesna | |
dc.creator | Srzentić, Sanja | |
dc.creator | Stanković, Biljana | |
dc.creator | Pavlović, Sonja | |
dc.date.accessioned | 2019-09-02T11:36:32Z | |
dc.date.available | 2019-09-02T11:36:32Z | |
dc.date.issued | 2013 | |
dc.identifier.issn | 0172-8172 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/1998 | |
dc.description.abstract | To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA. | en |
dc.publisher | Springer Heidelberg, Heidelberg | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175050/RS// | |
dc.rights | restrictedAccess | |
dc.source | Rheumatology International | |
dc.subject | -174G/C IL-6 polymorphism | en |
dc.subject | Rheumatoid arthritis | en |
dc.subject | Etanercept | en |
dc.subject | DAS28 improvement | en |
dc.title | -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Спасовски, Весна; Сефик-Букилица, Мирјана; Aрсеновић-Ранин, Невена; Срзентић, Сања; Дамјанов, Немања; Јанчић, Иван; Станковић, Биљана; Павловић, Соња; Живојиновић, Слађана; | |
dc.citation.volume | 33 | |
dc.citation.issue | 6 | |
dc.citation.spage | 1481 | |
dc.citation.epage | 1486 | |
dc.citation.other | 33(6): 1481-1486 | |
dc.citation.rank | M23 | |
dc.identifier.wos | 000319517000017 | |
dc.identifier.doi | 10.1007/s00296-012-2586-y | |
dc.identifier.pmid | 23233117 | |
dc.identifier.scopus | 2-s2.0-84878678926 | |
dc.type.version | publishedVersion |